Sandrine Censabella1, Stefan Claes2, Marc Orlandini3, Roel Braekers4, Paul Bulens5. 1. Jessa Hospital, Division of Medical Oncology, Stadsomvaart 11, 3500 Hasselt, Belgium. Electronic address: Sandrine.Censabella@jessazh.be. 2. Limburg Oncology Centre, Stadsomvaart 11, 3500 Hasselt, Belgium. Electronic address: Stefan.Claes@jessazh.be. 3. Limburg Oncology Centre, Stadsomvaart 11, 3500 Hasselt, Belgium. Electronic address: Marc.Orlandini@jessazh.be. 4. Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Agoralaan 1, B3590 Diepenbeek, Belgium; Catholic University of Leuven, Kapucijnenvoer 35, Blok D, Bus 7001, B3000 Leuven, Belgium. Electronic address: roel.braekers@uhasselt.be. 5. Limburg Oncology Centre, Stadsomvaart 11, 3500 Hasselt, Belgium. Electronic address: Paul.Bulens@jessazh.be.
Abstract
PURPOSE: Radiotherapy-induced moist desquamation (RIMD) is a complication that can affect patients' quality of life and jeopardize radiotherapy outcomes. The curative use of a hydroactive colloid gel has previously been shown effective in the management of RIMD in breast cancer patients. This study aimed at investigating the efficacy of this same gel but in the prevention of RIMD. METHODS: A group of breast cancer patients who applied the hydroactive gel from start to end of post-lumpectomy radiotherapy (Preventive Hydrogel group) were compared with two groups of matched historical controls: a group applying a dexpanthenol cream throughout their therapy and a group applying first the dexpanthenol cream then, after 11-14 fractions of radiotherapy, the hydroactive gel (Curative Hydrogel group). All patients received identical fractionation regimen. The clinical outcomes were the incidence and time to onset of RIMD. KEY RESULTS: After 25 fractions of radiotherapy (50 Gy), patients in the Preventive Hydrogel group (N = 202) developed RIMD significantly less frequently and later than patients in the Dexpanthenol group (N = 131; incidence = 7% vs 35% respectively, odds ratios = 7.27; probability of RIMD-free survival after 50 Gy = 0.88 vs 0.62). There were no significant differences between the Preventive and the Curative Hydrogel group (N = 87). CONCLUSIONS: These findings confirm our previous results: applying the hydroactive colloid gel, rather than dexpanthenol, delayed the onset and reduced the incidence of RIMD in breast cancer patients. However, applying the hydrogel preventively offered no statistically significant advantages over applying it curatively.
PURPOSE: Radiotherapy-induced moist desquamation (RIMD) is a complication that can affect patients' quality of life and jeopardize radiotherapy outcomes. The curative use of a hydroactive colloid gel has previously been shown effective in the management of RIMD in breast cancerpatients. This study aimed at investigating the efficacy of this same gel but in the prevention of RIMD. METHODS: A group of breast cancerpatients who applied the hydroactive gel from start to end of post-lumpectomy radiotherapy (Preventive Hydrogel group) were compared with two groups of matched historical controls: a group applying a dexpanthenol cream throughout their therapy and a group applying first the dexpanthenol cream then, after 11-14 fractions of radiotherapy, the hydroactive gel (Curative Hydrogel group). All patients received identical fractionation regimen. The clinical outcomes were the incidence and time to onset of RIMD. KEY RESULTS: After 25 fractions of radiotherapy (50 Gy), patients in the Preventive Hydrogel group (N = 202) developed RIMD significantly less frequently and later than patients in the Dexpanthenol group (N = 131; incidence = 7% vs 35% respectively, odds ratios = 7.27; probability of RIMD-free survival after 50 Gy = 0.88 vs 0.62). There were no significant differences between the Preventive and the Curative Hydrogel group (N = 87). CONCLUSIONS: These findings confirm our previous results: applying the hydroactive colloid gel, rather than dexpanthenol, delayed the onset and reduced the incidence of RIMD in breast cancerpatients. However, applying the hydrogel preventively offered no statistically significant advantages over applying it curatively.
Authors: Jolien Robijns; Sandrine Censabella; Stefan Claes; Luc Pannekoeke; Lore Bussé; Dora Colson; Iris Kaminski; Joy Lodewijckx; Paul Bulens; Annelies Maes; Leen Noé; Marc Brosens; An Timmermans; Ivo Lambrichts; Veerle Somers; Jeroen Mebis Journal: Support Care Cancer Date: 2018-10-01 Impact factor: 3.603